Between 1988 and 2017, there were significant global variations and trends in ovarian cancer incidence and its subtypes, ...

The therapeutic candidate is under development for the treatment of ovarian cancer. It comprises of induced pluripotent stem (iPS) cell derived natural killer (iNK) cell.

Faye Louise was diagnosed with a rare cancer that often requires multiple organs to be removed via surgery — but one year ...

In a new study led by researchers at Karolinska Institutet in Sweden, AI models did a better job of detecting ovarian cancer ...

Every woman has a one in 87 chance of getting ovarian cancer in her lifetime, and one in 130 will die from it.

A phase 1 trial evaluating FSHR-targeting CAR T cells for patients with ovarian cancer has dosed the first patient in its ...

Boehringer Ingelheim BioXcellence™ and Sutro Biopharma Inc.today announced that they successfully applied Sutro’ ...

A noninvasive method involving brief, localized pulses of magnetic fields could improve chemotherapy effectiveness and reduce ...

Onvapegleukin alfa is under clinical development by Ascendis Pharma and currently in Phase II for Ovarian Cancer.

A new international study led by researchers at Karolinska Institutet in Sweden shows that AI-based models can outperform ...